Health Care & Life Sciences » Biotechnology | Biotoxtech Co. Ltd.

Biotoxtech Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
17,272
15,088
16,676
22,257
25,565
Cost of Goods Sold (COGS) incl. D&A
12,934
12,418
12,854
15,007
16,098
Gross Income
4,338
2,670
3,822
7,249
9,467
SG&A Expense
5,606
6,639
6,379
4,812
7,096
EBIT
1,374
4,070
2,660
2,336
2,219
Unusual Expense
457
902
1,636
309
34
Non Operating Income/Expense
1,456
120
223
233
120
Interest Expense
451
530
506
487
488
Pretax Income
711
5,536
4,459
1,838
1,633
Income Tax
168
723
872
369
458
Equity in Affiliates
13
80
124
309
-
Consolidated Net Income
555
4,893
3,711
1,160
1,176
Net Income
83
4,526
3,905
1,045
1,392
Net Income After Extraordinaries
83
4,526
3,905
1,045
1,392
Net Income Available to Common
83
4,526
3,905
1,045
1,392
EPS (Basic)
6.96
394.63
274.34
72.59
96.00
Basic Shares Outstanding
12
11
14
14
14
EPS (Diluted)
6.96
394.52
274.34
72.59
96.33
Diluted Shares Outstanding
12
11
14
14
14
EBITDA
496
2,304
1,008
3,858
4,116
Other Operating Expense
106
101
103
101
151
Non-Operating Interest Income
115
86
118
65
83
Minority Interest Expense
472
366
194
115
216
Equity in Affiliates (Pretax)
-
-
-
-
267
Other After Tax Income (Expense)
-
1
-
-
-

About Biotoxtech Co.

View Profile
Address
Ochang Science Industrial Complex
Cheongju-si NC 28115
Korea, Republic Of
Employees -
Website http://www.biotoxtech.com
Updated 09/14/2018
Biotoxtech Co., Ltd. engages in the provision of non-clinical drugs trials. It operates through the following business divisions: Safety Evaluation Research Field, Efficacy Evaluation and Analysis Research Field. The Safety Evaluation Research Field offers studies such as general toxicity, local toxicity, reproductive and developmental, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology or hematology.